Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 2. Clinical Considerations and New Agents

Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis

Xia, Z., Dickens, M., Raingeaud, J., Davis, R. J., & Greenberg, M. E. (1995) · Science · doi:10.1126/science.270.5240.1326 · Cited by 5,287

Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene<SUBTITLE>Results From a 3-Year Randomized Clinical Trial</SUBTITLE>

Ettinger, B. (1999) · JAMA · doi:10.1001/jama.282.7.637 · Cited by 3,366

Molecular basis of agonism and antagonism in the oestrogen receptor

Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355

Transforming gene product of Rous sarcoma virus phosphorylates tyrosine

Hunter, T., & Sefton, B. M. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1311 · Cited by 2,332

Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene.

Lubahn, D. B., Moyer, J. S., Golding, T. S., Couse, J. F., Korach, K. S., & Smithies, O. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.23.11162 · Cited by 1,898

Differential Ligand Activation of Estrogen Receptors ERα and ERβ at AP1 Sites

Paech, K., Webb, P., Kuiper, G. G. J. M., Nilsson, S., Gustafsson, J.-Å., Kushner, P. J., & Scanlan, T. S. (1997) · Science · doi:10.1126/science.277.5331.1508 · Cited by 1,861

Generation and reproductive phenotypes of mice lacking estrogen receptor β

Krege, J. H., Hodgin, J. B., Couse, J. F., Enmark, E., Warner, M., Mahler, J. F., Sar, M., Korach, K. S., Gustafsson, J.-Å., & Smithies, O. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15677 · Cited by 1,691

Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women

Delmas, P. D., Bjarnason, N. H., Mitlak, B. H., Ravoux, A.-C., Shah, A. S., Huster, W. J., Draper, M., & Christiansen, C. (1997) · New England Journal of Medicine · doi:10.1056/nejm199712043372301 · Cited by 1,637

Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase

Simoncini, T., Hafezi-Moghadam, A., Brazil, D. P., Ley, K., Chin, W. W., & Liao, J. K. (2000) · Nature · doi:10.1038/35035131 · Cited by 1,436

Tamoxifen in the Treatment of Breast Cancer

Osborne, C. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811263392207 · Cited by 1,320

Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1

Biggs, W. H., Meisenhelder, J., Hunter, T., Cavenee, W. K., & Arden, K. C. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7421 · Cited by 1,116

Nongenotropic, Sex-Nonspecific Signaling through the Estrogen or Androgen Receptors

Kousteni, S., Bellido, T., Plotkin, L. I., O'Brien, C. A., Bodenner, D. L., Han, L., Han, K., DiGregorio, G. B., Katzenellenbogen, J. A., Katzenellenbogen, B. S., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00268-9 · Cited by 1,113

Protein kinase activity associated with the avian sarcoma virus src gene product.

Collett, M. S., & Erikson, R. L. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.4.2021 · Cited by 1,105

Untitled work

(1991) · PubMed · Cited by 1,101

Cell Membrane and Nuclear Estrogen Receptors (ERs) Originate from a Single Transcript: Studies of ERα and ERβ Expressed in Chinese Hamster Ovary Cells

Razandi, M., Pedram, A., Greene, G. L., & Levin, E. R. (1999) · Molecular Endocrinology · doi:10.1210/mend.13.2.0239 · Cited by 1,040

Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist

Pike, A. C. W. (1999) · The EMBO Journal · doi:10.1093/emboj/18.17.4608 · Cited by 986

Tissue Distribution and Quantitative Analysis of Estrogen Receptor-α (ERα) and Estrogen Receptor-β (ERβ) Messenger Ribonucleic Acid in the Wild-Type and ERα-Knockout Mouse

Couse, J. F., Lindzey, J., Grandien, K., Gustafsson, J.-A., & Korach, K. S. (1997) · Endocrinology · doi:10.1210/endo.138.11.5496 · Cited by 978

Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α

Campbell, R. A., Bhat-Nakshatri, P., Patel, N. M., Constantinidou, D., Ali, S., & Nakshatri, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010840200 · Cited by 968

Display and Analysis of Patterns of Differential Activity of Drugs Against Human Tumor Cell Lines: Development of Mean Graph and COMPARE Algorithm

Paull, K. D., Shoemaker, R. H., Hodes, L., Monks, A., Scudiero, D. A., Rubinstein, L., Plowman, J., & Boyd, M. R. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.14.1088 · Cited by 967

Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells.

Migliaccio, A., Di Domenico, M., Castoria, G., de Falco, A., Bontempo, P., Nola, E., & Auricchio, F. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00471.x · Cited by 959

Five Versus More Than Five Years of Tamoxifen Therapy for Breast Cancer Patients With Negative Lymph Nodes and Estrogen Receptor-Positive Tumors

Fisher, B., Dignam, J., Bryant, J., DeCillis, A., Wickerham, D. L., Wolmark, N., Costantino, J., Redmond, C., Fisher, E. R., Bowman, D. M., et al. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.21.1529 · Cited by 861

Pyrazole Ligands: Structure−Affinity/Activity Relationships and Estrogen Receptor-α-Selective Agonists

Stauffer, S. R., Coletta, C. J., Tedesco, R., Nishiguchi, G., Carlson, K., Sun, J., Katzenellenbogen, B. S., & Katzenellenbogen, J. A. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000170m · Cited by 760

Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

Benz, C. C., Scott, G. K., Sarup, J. C., Johnson, R. M., Tripathy, D., Coronado, E., Shepard, H. M., & Osborne, C. K. (1992) · Breast Cancer Research and Treatment · doi:10.1007/bf01961241 · Cited by 750

Effects of Raloxifene on Serum Lipids and Coagulation Factors in Healthy Postmenopausal Women

Walsh, B. W. (1998) · JAMA · doi:10.1001/jama.279.18.1445 · Cited by 692

Partial Hormone Resistance in Mice with Disruption of the Steroid Receptor Coactivator-1 (SRC-1) Gene

Xu, J., Qiu, Y., DeMayo, F. J., Tsai, S. Y., Tsai, M.-J., & O'Malley, B. W. (1998) · Science · doi:10.1126/science.279.5358.1922 · Cited by 684

Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial

Cauley, J. A., Norton, L., Lippman, M. E., Eckert, S., Krueger, K. A., Purdie, D. W., Farrerons, J., Karasik, A., Mellstrom, D., Ng, K. W., et al. (2001) · Breast Cancer Research and Treatment · doi:10.1023/a:1006478317173 · Cited by 678

Estrogen Receptor-β Potency-Selective Ligands: Structure−Activity Relationship Studies of Diarylpropionitriles and Their Acetylene and Polar Analogues

Meyers, M. J., Sun, J., Carlson, K. E., Marriner, G. A., Katzenellenbogen, B. S., & Katzenellenbogen, J. A. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010254a · Cited by 678

Fulvestrant, Formerly ICI 182,780, Is as Effective as Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing After Prior Endocrine Treatment

Howell, A., Robertson, J. F. R., Quaresma Albano, J., Aschermannova, A., Mauriac, L., Kleeberg, U. R., Vergote, I., Erikstein, B., Webster, A., & Morris, C. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.057 · Cited by 671

Evidence that the transforming gene of avian sarcoma virus encodes a protein kinase associated with a phosphoprotein

Levinson, A. D., Oppermann, H., Levintow, L., Varmus, H. E., & Bishop, J. M. (1978) · Cell · doi:10.1016/0092-8674(78)90024-7 · Cited by 653

Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.

Powles, T. J., Hickish, T., Kanis, J. A., Tidy, A., & Ashley, S. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.78 · Cited by 646

Double-Blind, Randomized Trial Comparing the Efficacy and Tolerability of Fulvestrant Versus Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing on Prior Endocrine Therapy: Results of a North American Trial

Osborne, C. K., Pippen, J., Jones, S. E., Parker, L. M., Ellis, M., Come, S., Gertler, S. Z., May, J. T., Burton, G., Dimery, I., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.058 · Cited by 642

The Mitogen-Activated Protein Kinase Pathway Mediates Estrogen Neuroprotection after Glutamate Toxicity in Primary Cortical Neurons

Singer, C. A., Figueroa-Masot, X. A., Batchelor, R. H., & Dorsa, D. M. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-07-02455.1999 · Cited by 577

Tyr 527 Is Phosphorylated in pp60 c- src : Implications for Regulation

Cooper, J. A., Gould, K. L., Cartwright, C. A., & Hunter, T. (1986) · Science · doi:10.1126/science.2420005 · Cited by 540

Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial

Kedar, R., Bourne, T. H., Collins, W. P., Campbell, S., Powles, T. J., Ashley, S., & Cosgrove, D. O. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92466-x · Cited by 531

The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling

Dauvois, S., White, R., & Parker, M. G. (1993) · Journal of Cell Science · doi:10.1242/jcs.106.4.1377 · Cited by 522

Adjuvant Tamoxifen Therapy for Early Stage Breast Cancer and Second Primary Malignancies

Rutqvist, L. E., Johansson, H., Signomklao, T., Johansson, U., Fornander, T., & Wilking, N. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.9.645 · Cited by 508

A MONOHYDROXYLATED METABOLITE OF TAMOXIFEN WITH POTENT ANTIOESTROGENIC ACTIVITY

JORDAN, V. C., COLLINS, M. M., ROWSBY, L., & PRESTWICH, G. (1977) · Journal of Endocrinology · doi:10.1677/joe.0.0750305 · Cited by 506

Structure at 1.65 Å of RhoA and its GTPase-activating protein in complex with a transition-state analogue

Rittinger, K., Walker, P. A., Eccleston, J. F., Smerdon, S. J., & Gamblin, S. J. (1997) · Nature · doi:10.1038/39651 · Cited by 490

Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover.

Dauvois, S., Danielian, P. S., White, R., & Parker, M. G. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.9.4037 · Cited by 465

Evidence that the Rous sarcoma virus transforming gene product phosphorylates phosphatidylinositol and diacylglycerol.

Sugimoto, Y., Whitman, M., Cantley, L. C., & Erikson, R. L. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.7.2117 · Cited by 462

The Human Estrogen Receptor-α Is a Ubiquitinated Protein Whose Stability Is Affected Differentially by Agonists, Antagonists, and Selective Estrogen Receptor Modulators

Wijayaratne, A. L., & McDonnell, D. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101097200 · Cited by 427

Combined Tamoxifen and Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Versus LHRH Agonist Alone in Premenopausal Advanced Breast Cancer: A Meta-Analysis of Four Randomized Trials

Klijn, J. G. M., Blamey, R. W., Boccardo, F., Tominaga, T., Duchateau, L., & Sylvester, R. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.343 · Cited by 425

Untitled work

(1988) · PubMed · Cited by 416

Use of tamoxifen for breast cancer: twenty-eight years later.

Jaiyesimi, I. A., Buzdar, A. U., Decker, D. A., & Hortobagyi, G. N. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.2.513 · Cited by 413

Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice.

Osborne, C. K., Hobbs, K., & Clark, G. M. (1985) · PubMed · Cited by 402

The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia.

Arteaga, C. L. (2001) · PubMed · Cited by 397

Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization.

Fawell, S. E., White, R., Hoare, S., Sydenham, M., Page, M., & Parker, M. G. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.17.6883 · Cited by 396

The Estrogen Receptor Enhances AP-1 Activity by Two Distinct Mechanisms with Different Requirements for Receptor Transactivation Functions

Webb, P. M., Nguyen, P. T., Valentine, C. D., Lopez, G. N., Kwok, G. R., McInerney, E. M., Katzenellenbogen, B. S., Enmark, E., Gustafsson, J.-Α., Nilsson, S. V., et al. (1999) · Molecular Endocrinology · doi:10.1210/me.13.10.1672 · Cited by 396

Acute respiratory-tract infections and risk of first-time acute myocardial infarction

Meier, C. R., Jick, S. S., Derby, L. E., Vasilakis, C., Jick, H., Meier, C., Jick, S., Derby, L., Vasilakis, C., & Jick, H. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11084-4 · Cited by 389

Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer

Wright, C., Nicholson, S., Angus, B., Sainsbury, J., Farndon, J., Cairns, J., Harris, A., & Horne, C. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.22 · Cited by 379

Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle.

Musgrove, E. A., Lee, C. S., Buckley, M. F., & Sutherland, R. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.17.8022 · Cited by 376

Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee.

McDonald, C. C., & Stewart, H. J. (1991) · BMJ · doi:10.1136/bmj.303.6800.435 · Cited by 365

Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells.

Kurokawa, H., Lenferink, A. E. G., Simpson, J. F., Pisacane, P. I., Sliwkowski, M. X., Forbes, J. T., & Arteaga, C. L. (2000) · PubMed · Cited by 363

Estrogen receptor β acts as a dominant regulator of estrogen signaling

Pettersson, K., Delaunay, F., & Gustafsson, J.-Å. (2000) · Oncogene · doi:10.1038/sj.onc.1203828 · Cited by 362

Comparison of the Effects of a Pure Steroidal antiestrogen With Those of Tamoxifen in a Model of Human Breast Cancer

Osborne, C. K., Coronado-Heinsohn, E. B., Hilsenbeck, S. G., McCue, B. L., Wakeling, A. E., McCleland, R. A., Manning, D. L., & Nicholson, R. I. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.10.746 · Cited by 361

Tamoxifen Therapy for Breast Cancer and Endometrial Cancer Risk

Bernstein, L., Deapen, D., Cerhan, J. R., Schwartz, S. M., Liff, J., McGann-Maloney, E., Perlman, J. A., & Ford, L. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.19.1654 · Cited by 358

Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism

Shiau, A. K., Barstad, D., Radek, J. T., Meyers, M. J., Nettles, K. W., Katzenellenbogen, B. S., Katzenellenbogen, J. A., Agard, D. A., & Greene, G. L. (2002) · Nature Structural Biology · doi:10.1038/nsb787 · Cited by 356

Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer

Howell, A., DeFriend, D. J., Blamey, R. W., Robertson, J. F., & Walton, P. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91156-1 · Cited by 349

Structural Insights into the Mode of Action of a Pure Antiestrogen

Pike, A. C. W., Brzozowski, A. M., Walton, J., Hubbard, R. E., Thorsell, A.-G., Li, Y.-L., Gustafsson, J.-Å., & Carlquist, M. (2001) · Structure · doi:10.1016/s0969-2126(01)00568-8 · Cited by 347

Cyclin D1 Is Required for Transformation by Activated Neu and Is Induced through an E2F-Dependent Signaling Pathway

Lee, R. J., Albanese, C., Fu, M., D'Amico, M., Lin, B., Watanabe, G., Haines, G. K., Siegel, P. M., Hung, M.-C., Yarden, Y., et al. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.2.672-683.2000 · Cited by 347

Cardiac and Thromboembolic Morbidity Among Postmenopausal Women With Early Stage Breast Cancer in a Randomized Trial of Adjuvant Tamoxifen

Rutqvist, L. E., & Anders Mattsson for the Stockholm Breast Cancer Study Group (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.17.1398 · Cited by 334

Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers.

Sjögren, S., Inganäs, M., Lindgren, A., Holmberg, L., & Bergh, J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.462 · Cited by 327

Stress-activated Protein Kinases: Activation, Regulation and Function

Paul, A., Wilson, S., Belham, C. M., Robinson, C. J. M., Scott, P. H., Gould, G. W., & Plevin, R. (1997) · Cellular Signalling · doi:10.1016/s0898-6568(97)00042-9 · Cited by 321

STEROIDAL PURE ANTIOESTROGENS

Wakeling, A. E., & Bowler, J. (1987) · Journal of Endocrinology · doi:10.1677/joe.0.112r007 · Cited by 321

Novel Ligands that Function as Selective Estrogens or Antiestrogens for Estrogen Receptor-α or Estrogen Receptor-β*

Sun, J., Meyers, M. J., Fink, B. E., Rajendran, R., Katzenellenbogen, J. A., & Katzenellenbogen, B. S. (1999) · Endocrinology · doi:10.1210/endo.140.2.6480 · Cited by 315

Proteasome-Mediated Proteolysis of Estrogen Receptor: A Novel Component in Autologous Down-Regulation

Alarid, E. T. (1999) · Molecular Endocrinology · doi:10.1210/me.13.9.1522 · Cited by 300

Aromatase Inhibitors in the Treatment and Prevention of Breast Cancer

Goss, P. E., & Strasser, K. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.881 · Cited by 298

Effect of Long-Term Estrogen Deprivation on Apoptotic Responses of Breast Cancer Cells to 17 -Estradiol

Song, R. X.-D., Mor, G., Naftolin, F., McPherson, R. A., Song, J., Zhang, Z., Yue, W., Wang, J., & Santen, R. J. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.22.1714 · Cited by 293

Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer.

DeFriend, D. J., Howell, A., Nicholson, R. I., Anderson, E., Dowsett, M., Mansel, R. E., Blamey, R. W., Bundred, N. J., Robertson, J. F. R., & Saunders, C. M. (1994) · PubMed · Cited by 291

Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells.

Sutherland, R. L., Hall, R. E., & Taylor, I. W. (1983) · PubMed · Cited by 285

Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl]-[4-[2-(1-piperidinyl)ethoxy]phenyl]methanone hydrochloride (LY 156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity

Jones, C. D., Jevnikar, M. G., Pike, A. J., Peters, M. K., Black, L. J., Thompson, A. R., Falcone, J. F., & Clemens, J. A. (1984) · Journal of Medicinal Chemistry · doi:10.1021/jm00374a021 · Cited by 283

p38 Kinase Mediates UV-induced Phosphorylation of p53 Protein at Serine 389

Huang, C., Ma, W.-Y., Maxiner, A., Sun, Y., & Dong, Z. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.18.12229 · Cited by 275

c-Src PROTEIN EXPRESSION IS INCREASED IN HUMAN BREAST CANCER. AN IMMUNOHISTOCHEMICAL AND BIOCHEMICAL ANALYSIS

VERBEEK, B. S., VROOM, T. M., ADRIAANSEN-SLOT, S. S., OTTENHOFF-KALFF, A. E., GEERTZEMA, J. G. N., HENNIPMAN, A., & RIJKSEN, G. (1996) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199612)180:4<383::aid-path686>3.0.co;2-n · Cited by 270

Transcription Activation by the Human Estrogen Receptor Subtypeβ (ERβ) Studied with ERβ and ERα Receptor Chimeras1

McInerney, E. M., Weis, K. E., Sun, J., Mosselman, S., & Katzenellenbogen, B. S. (1998) · Endocrinology · doi:10.1210/endo.139.11.6298 · Cited by 269

Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor.

Hyder, S. M., Nawaz, Z., Chiappetta, C., & Stancel, G. M. (2000) · PubMed · Cited by 268

A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer

Powles, T., Hardy, Jr., Ashley, S., Farrington, G., Cosgrove, D., Davey, J., Dowsett, M., McKinna, J., Nash, A., Sinnett, H., et al. (1989) · British Journal of Cancer · doi:10.1038/bjc.1989.235 · Cited by 246

ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer

Borg, Å., Baldetorp, B., Fernö, M., Killander, D., Olsson, H., Ryden, S., & Sigurdsson, H. (1994) · Cancer Letters · doi:10.1016/0304-3835(94)90194-5 · Cited by 246

Comparative Analyses of Mechanistic Differences Among Antiestrogens1

Wijayaratne, A. L., Nagel, S. C., Paige, L. A., Christensen, D. J., Norris, J. D., Fowlkes, D. M., & McDonnell, D. P. (1999) · Endocrinology · doi:10.1210/endo.140.12.7164 · Cited by 244

Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients.

Speirs, V., Malone, C. M., Walton, D. S., Kerin, M. J., & Atkin, S. L. (1999) · PubMed · Cited by 237

Antagonists Selective for Estrogen Receptor α

Sun, J., Huang, Y. R., Harrington, W. R., Sheng, S., Katzenellenbogen, J. A., & Katzenellenbogen, B. S. (2002) · Endocrinology · doi:10.1210/endo.143.3.8704 · Cited by 236

Coexpression of estrogen receptor alpha and beta: poor prognostic factors in human breast cancer?

Speirs, V., Parkes, A., Kerin, M. J., Walton, D. S., Carleton, P. J., Fox, J. N., & Atkin, S. L. (1999) · PubMed · Cited by 234

A NON-STEROIDAL ESTROGEN ANTAGONIST l-(p-2-DIETHYLAMINOETHOXYPHENYLH-PHENYL-2-p-METHOXYPHENYL ETHANOL

LERNER, L. J., HOLTHAUS, F. J., & THOMPSON, C. R. (1958) · Endocrinology · doi:10.1210/endo-63-3-295 · Cited by 233

Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity.

Muthuswamy, S. K., Siegel, P. M., Dankort, D. L., Webster, M. A., & Muller, W. J. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.1.735 · Cited by 228

High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy

Lønning, P. E., Taylor, P. D., Anker, G., Iddon, J., Wie, L., Jørgensen, L.-M., Mella, O., & Howell, A. (2001) · Breast Cancer Research and Treatment · doi:10.1023/a:1010619225209 · Cited by 226

Analysis of the MRP4 Drug Resistance Profile in Transfected NIH3T3 Cells

Lee, K. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.23.1934 · Cited by 222

Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer

Houston, S. J., Plunkett, T. A., Barnes, D. M., Smith, P., Rubens, R. D., & Miles, D. W. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690196 · Cited by 220

Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer.

Hayes, D. F., Van Zyl, J. A., Hacking, A., Goedhals, L., Bezwoda, W. R., Mailliard, J. A., Jones, S. E., Vogel, C. L., Berris, R. F., & Shemano, I. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.10.2556 · Cited by 216

Novel antioestrogens without partial agonist activity

Wakeling, A. E., & Bowler, J. (1988) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(88)90014-3 · Cited by 214

Estrogen Receptor (ER)α and ERβ Exhibit Unique Pharmacologic Properties When Coupled to Activation of the Mitogen-Activated Protein Kinase Pathway*

Wade, C. B., Robinson, S., Shapiro, R. A., & Dorsa, D. M. (2001) · Endocrinology · doi:10.1210/endo.142.6.8071 · Cited by 213

Long-term Effects of Raloxifene on Bone Mineral Density, Bone Turnover, and Serum Lipid Levels in Early Postmenopausal Women: Three-Year Data From 2 Double-blind, Randomized, Placebo-Controlled Trials

Johnston, C. C., Bjarnason, N. H., Cohen, F. J., Shah, A., Lindsay, R., Mitlak, B. H., Huster, W., Draper, M. W., Harper, K. D., Heath, H., et al. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.22.3444 · Cited by 211

Oxidative Stress and AP-1 Activity in Tamoxifen-Resistant Breast Tumors In Vivo

Schiff, R. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.23.1926 · Cited by 211

The Distribution of Estrogen Receptor-β mRNA in Forebrain Regions of the Estrogen Receptor-α Knockout Mouse

Shughrue, P., Scrimo, P., Lane, M., Askew, R., & Merchenthaler, I. (1997) · Endocrinology · doi:10.1210/endo.138.12.5712 · Cited by 208

Novel steroidal pure antiestrogens

Bowler, J., Lilley, T. J., Pittam, J. D., & Wakeling, A. E. (1989) · Steroids · doi:10.1016/0039-128x(89)90076-7 · Cited by 206

Estrogen Receptors α and β: Prevalence of Estrogen Receptor β mRNA in Human Vascular Smooth Muscle and Transcriptional Effects

Hodges, Y. K., Tung, L., Yan, X.-D., Graham, J. D., Horwitz, K. B., & Horwitz, L. D. (2000) · Circulation · doi:10.1161/01.cir.101.15.1792 · Cited by 202

Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2.

Janes, P. W., Daly, R. J., DeFazio, A., & Sutherland, R. L. (1994) · PubMed · Cited by 199

The Mechanism of ICI 164,384 Antiestrogenieity Involves Rapid Loss of Estrogen Receptor in Uterine Tissue

GIBSON, M. K., NEMMERS, L. A., BECKMAN, W. C., DAVIS, V. L., CURTIS, S. W., & KORACH, K. S. (1991) · Endocrinology · doi:10.1210/endo-129-4-2000 · Cited by 198

MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.

Brünner, N., Boysen, B., JIRUS, S., Skaar, T. C., Holst‐Hansen, C., Lippman, J., Frandsen, T. L., Spang‐Thomsen, M., Fuqua, S. A. W., & Clarke, R. C. (1997) · PubMed · Cited by 196

Effects of Tamoxifen on Spinal Bone Density in Women With Breast Cancer

Turken, S., Siris, E., Seldin, D., Flaster, E., Hyman, G., & Lindsay, R. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.14.1086 · Cited by 194

Differential Interaction of the Methoxychlor Metabolite 2,2-Bis-(p-Hydroxyphenyl)-1,1,1-Trichloroethane with Estrogen Receptors α and β1

Gaido, K. W., Leonard, L. S., Maness, S. C., Hall, J. M., McDonnell, D. P., Saville, B., & Safe, S. (1999) · Endocrinology · doi:10.1210/endo.140.12.7191 · Cited by 190

Epidermal growth factor receptor expression in breast cancer: Association with response to endocrine therapy

Nicholson, R. I., McClelland, R. A., Gee, J. M. W., Manning, D. L., Cannon, P., Robertson, J. F. R., Ellis, I. O., & Blamey, R. W. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00666187 · Cited by 190

Human breast cancer in the athymic nude mouse: Cystostatic effects of long-term antiestrogen therapy

Kent Osborne, C., Coronado, E. B., & Robinson, J. P. (1987) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(87)90154-4 · Cited by 187

Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation

Watts, C. K. (1995) · Molecular Endocrinology · doi:10.1210/me.9.12.1804 · Cited by 185

HER-2/neu and p53 Expression Versus Tamoxifen Resistance in Estrogen Receptor–Positive, Node-Positive Breast Cancer

Berry, D. A., Muss, H. B., Thor, A. D., Dressler, L., Liu, E. T., Broadwater, G., Budman, D. R., Henderson, I. C., Barcos, M., Hayes, D., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.20.3471 · Cited by 180

Inhibition of angiogenesis by antiestrogens.

Gagliardi, A., & Collins, D. C. (1993) · PubMed · Cited by 179

Discovery and Synthesis of [6-Hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- 2-(4-hydroxyphenyl)]benzo[b]thiophene: A Novel, Highly Potent, Selective Estrogen Receptor Modulator

Palkowitz, A. D., Glasebrook, A. L., Thrasher, K. J., Hauser, K. L., Short, L. L., Phillips, D. L., Muehl, B. S., Sato, M., Shetler, P. K., Cullinan, G. J., et al. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm970167b · Cited by 177

Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels

Clemens, J. A., Bennett, D. R., Black, L. J., & Jones, C. D. (1983) · Life Sciences · doi:10.1016/0024-3205(83)90323-5 · Cited by 176

Structure−Activity Relationships of Selective Estrogen Receptor Modulators: Modifications to the 2-Arylbenzothiophene Core of Raloxifene

Grese, T. A., Cho, S., Finley, D. R., Godfrey, A. G., Jones, C. D., Lugar, C. W., Martin, M. J., Matsumoto, K., Pennington, L. D., Winter, M. A., et al. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm9606352 · Cited by 176

Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment

Berns, E. M. J. J., Foekens, J. A., van Staveren, I. L., van Putten, W. L. J., de Koning, H. Y. W. C. M., Portengen, H., & Klijn, J. G. M. (1995) · Gene · doi:10.1016/0378-1119(94)00534-y · Cited by 173

Original article: Response after withdrawal of tamoxifen and progestogens in advanced breast cancer

Howell, A., Dodwell, D. J., Anderson, H., & Redford, J. (1992) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058286 · Cited by 172

Expression of pp60c-src protein kinase in adult and fetal human tissue: high activities in some sarcomas and mammary carcinomas.

Jacobs, C., & Rübsamen, H. (1983) · PubMed · Cited by 167

EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium

Labrie, F., Labrie, C., Bélanger, A., Simard, J., Gauthier, S., Luu-The, V., Mérand, Y., Giguere, V., Candas, B., Luo, S., et al. (1999) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(99)00065-5 · Cited by 163

Effects of CP-336,156, a New, Nonsteroidal Estrogen Agonist/Antagonist, on Bone, Serum Cholesterol, Uterus, and Body Composition in Rat Models

Ke, H. Z., Paralkar, V. M., GRASSER, W. A., Crawford, D. T., Qi, H., Simmons, H. A., Pirie, C. M., Chidsey-Frink, K. L., Owen, T. A., Smock, S. L., et al. (1998) · Endocrinology · doi:10.1210/endo.139.4.5902 · Cited by 161

The quinone reductase gene: A unique estrogen receptor-regulated gene that is activated by antiestrogens

Montano, M. M., & Katzenellenbogen, B. S. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2581 · Cited by 159

Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy

Archer, S., Eliopoulos, A., Spandidos, D., Barnes, D., Ellis, I., Blamey, R., Nicholson, R., & Robertson, J. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.497 · Cited by 159

(S)-(+)-4-[7-(2,2-Dimethyl-1-oxopro- poxy)-4-methyl-2-[4-[2-(1-piperidinyl)- ethoxy]phenyl]-2H-1-benzopyran-3-yl]- phenyl 2,2-Dimethylpropanoate (EM-800): A Highly Potent, Specific, and Orally Active Nonsteroidal Antiestrogen

Gauthier, S., Caron, B., Cloutier, J., Dory, Y. L., Favre, A., Larouche, D., Mailhot, J., Ouellet, C., Schwerdtfeger, A., Leblanc, G., et al. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm970095o · Cited by 157

Forkhead Homologue in Rhabdomyosarcoma Functions as a Bifunctional Nuclear Receptor-interacting Protein with Both Coactivator and Corepressor Functions

Zhao, H. H., Herrera, R. E., Coronado, E. B., Yang, M., Ludes-Meyers, J. H., Seybold-Tilson, K. J., Nawaz, Z., Yee, D., Barr, F. G., Diab, S., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104278200 · Cited by 154

Coronary Heart Disease Mortality and Adjuvant Tamoxifen Therapy

Costantino, J. P., Dignam, J. J., Kuller, L. H., et al. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.11.776 · Cited by 153

Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women.

Shewmon, D. A., Stock, J. L., Rosen, C. J., Heiniluoma, K. M., Hogue, M., Morrison, A., Doyle, E. M., UKENA, T. E., Weale, V., & Baker, S. (1994) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.14.10.1586 · Cited by 150

Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: A model to study the tumoristatic action of tamoxifen

Gottardis, M. M., Robinson, S. P., & Jordan, V. C. (1988) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(88)90113-6 · Cited by 147

3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic Acid: A Non-Steroidal Estrogen with Functional Selectivity for Bone over Uterus in Rats

Willson, T. M., Henke, B. R., Momtahen, T. M., Charifson, P. S., Batchelor, K. W., Lubahn, D. B., Moore, L. B., Oliver, B. B., Sauls, H. R., Triantafillou, J. A., et al. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00037a002 · Cited by 146

Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer.

Saarto, T., BLOMQVIST, C. P., Ehnholm, C., Taskinen, M., & Elomaa, I. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.2.429 · Cited by 145

A Pure Estrogen Antagonist Inhibits Cyclin E-Cdk2 Activity in MCF-7 Breast Cancer Cells and Induces Accumulation of p130-E2F4 Complexes Characteristic of Quiescence

Carroll, J. S., Prall, O. W. J., Musgrove, E. A., & Sutherland, R. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004424200 · Cited by 144

Oestrogen receptor: a stable phenotype in breast cancer

Robertson, J. F. R. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.2 · Cited by 143

Pharmacology of tamoxifen in laboratory animals.

Jordan, V. C., Allen, K. E., & DIX, C. J. (1981) · PubMed · Cited by 142

A realistic clinical perspective of tamoxifen and endometrial carcinogenesis

Assikis, V. J., Neven, P., Jordan, V. C., et al. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00184-0 · Cited by 142

Effects of the Antiestrogens Tamoxifen, Toremifene, and ICI 182,780 on Endometrial Cancer Growth

O'Regan, R. M., Cisneros, A., MacGregor, J. L., Muenzner, H. D., Assikis, V. J., Piette, M., Jordan, V. C., England, G. M., Bilimoria, M. M., Chatterton, R. T., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.20.1552 · Cited by 140

Design, Synthesis, and Preclinical Characterization of Novel, Highly Selective Indole Estrogens

Miller, C. P., Collini, M. D., Tran, B. D., Harris, H. A., Kharode, Y. P., Marzolf, J. T., Moran, R. A., Henderson, R. A., Bender, R. H. W., Unwalla, R. J., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010086m · Cited by 137

LY353381.HCl: A Novel Raloxifene Analog with Improved SERM Potency and Efficacy In Vivo

Sato, M., Turner, C. H., Wang, T., Adrian, M. D., Rowley, E. R., & Bryant, H. U. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37755-9 · Cited by 136

Discovery and Preclinical Pharmacology of a Novel, Potent, Nonsteroidal Estrogen Receptor Agonist/Antagonist, CP-336156, a Diaryltetrahydronaphthalene

Rosati, R. L., Jardine, P. D. S., Cameron, K. O., et al. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm980048b · Cited by 135

Estrogen receptor-beta messenger RNA expression in human breast tumor biopsies: relationship to steroid receptor status and regulation by progestins.

Dotzlaw, H., Leygue, E., Watson, P. H., & Murphy, L. C. (1999) · PubMed · Cited by 134

Specific DNA Probe for the Diagnosis of Plasmodium falciparum Malaria

Barker, R. H., Suebsaeng, L., Rooney, W., Alecrim, G. C., Dourado, H. V., & Wirth, D. F. (1986) · Science · doi:10.1126/science.3513309 · Cited by 133

The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth

Osborne, C. K., Jarman, M., McCague, R., Coronado, E. B., Hilsenbeck, S. G., & Wakeling, A. E. (1994) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685924 · Cited by 133

Transcriptional Regulation of the Human Quinone Reductase Gene by Antiestrogen-liganded Estrogen Receptor-α and Estrogen Receptor-β

Montano, M. M., Jaiswal, A. K., & Katzenellenbogen, B. S. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.39.25443 · Cited by 133

Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor.

Connor, C. E., Norris, J. D., Broadwater, G., Willson, T. M., Gottardis, M. M., Dewhirst, M. W., & McDonnell, D. P. (2001) · PubMed · Cited by 131

Dissection of the Molecular Mechanism of Action of GW5638, a Novel Estrogen Receptor Ligand, Provides Insights into the Role of Estrogen Receptor in Bone

Willson, T. M., Norris, J. D., Wagner, B. L., Asplin, I., Baer, P. G., Brown, H. R., Jones, S. A., Henke, B. R., Sauls, H. R., Wolfe, S. G., et al. (1997) · Endocrinology · doi:10.1210/en.138.9.3901 · Cited by 131

Coactivator Peptides Have a Differential Stabilizing Effect on the Binding of Estrogens and Antiestrogens with the Estrogen Receptor

Gee, A. C., Carlson, K. E., Martini, P. G. V., Katzenellenbogen, B. S., & Katzenellenbogen, J. A. (1999) · Molecular Endocrinology · doi:10.1210/mend.13.11.0373 · Cited by 130

CALCIUM BALANCE IN PREGNANCY

Duggin, G. G., Dale, N. E., Lyneham, R. C., Evans, R. A., & TILLER, D. J. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92395-8 · Cited by 129

Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice.

Gottardis, M. M., Ricchio, M. E., SATYASWAROOP, P. G., et al. (1990) · PubMed · Cited by 128

Synthesis and Pharmacology of Conformationally Restricted Raloxifene Analogues: Highly Potent Selective Estrogen Receptor Modulators

Grese, T. A., Pennington, L. D., Sluka, J. P., Adrian, M. D., Cole, H. W., Fuson, T. R., Magee, D. E., Phillips, D. L., Rowley, E. R., Shetler, P. K., et al. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm970688z · Cited by 126

Understanding the genotoxicity of tamoxifen?

Phillips, D. H. (2001) · Carcinogenesis · doi:10.1093/carcin/22.6.839 · Cited by 125

Adjuvant tamoxifen in primary breast cancer: Influence on plasma lipids and antithrombin III levels

Bertelli, G., Pronzato, P., AMOROSO, D., Cusimano, M. P., Conte, P., Montagna, G., Bertolini, S., & Rosso, R. (1988) · Breast Cancer Research and Treatment · doi:10.1007/bf01811244 · Cited by 123

Nonsteroidal antiestrogens: Their biological effects and potential mechanisms of action

Jordan, V. C., DIX, C. J., Naylor, K. E., Prestwich, G., & Rowsby, L. (1978) · Journal of Toxicology and Environmental Health · doi:10.1080/15287397809529666 · Cited by 123

Value of Epidermal Growth Factor Receptor, HER2, p53, and Steroid Receptors in Predicting the Efficacy of Tamoxifen in High-Risk Postmenopausal Breast Cancer Patients

Knoop, A. S., Bentzen, S. M., Nielsen, M. M., Rasmussen, B., & Rose, C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3376 · Cited by 122

Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen.

Ravdin, P., Fritz, N. F., Tormey, D. C., & Jordan, V. C. (1988) · PubMed · Cited by 122

Tamoxifen enhances cell death in implanted MCF7 breast cancer by inhibiting endothelium growth.

Haran, E. F., Maretzek, A., Goldberg, I. D., Horowitz, A., & Degani, H. (1994) · PubMed · Cited by 121

New biospecific adsorbents for the purification of estradiol receptor.

Bucourt, R., Vignau, M., & TORELLI, V. (1978) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)34385-5 · Cited by 121

Potentiation of Estrogen Receptor Activation Function 1 (AF-1) by Src/JNK through a Serine 118-Independent Pathway

Feng, W., Webb, P., Nguyen, P. T., Liu, X., Li, J., Karin, M., & Kushner, P. J. (2001) · Molecular Endocrinology · doi:10.1210/mend.15.1.0590 · Cited by 121

Selective Estrogenic Effects of a Novel Triphenylethylene Compound, FC1271a, on Bone, Cholesterol Level, and Reproductive Tissues in Intact and Ovariectomized Rats1

Qu, Q., Zheng, H., Dahllund, J., Laine, A. M., Cockcroft, N., Peng, Z., Koskinen, M., Hemminki, K., Kangas, L., Väänänen, K., et al. (2000) · Endocrinology · doi:10.1210/endo.141.2.7342 · Cited by 120

Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens.

Wilcken, N. R. C., Prall, O. W. J., Musgrove, E. A., & Sutherland, R. L. (1997) · PubMed · Cited by 118

Comparison between the Effects of Tamoxifen and Toremifene on the Uterus in Postmenopausal Breast Cancer Patients

Tomás, E. I., Kauppila, A., BLANCO, G., et al. (1995) · Gynecologic Oncology · doi:10.1006/gyno.1995.0019 · Cited by 117

Lasofoxifene (CP-336,156), a Selective Estrogen Receptor Modulator, Prevents Bone Loss Induced by Aging and Orchidectomy in the Adult Rat

Ke, H. Z., Qi, H., Crawford, D. T., Chidsey-Frink, K. L., Simmons, H. A., & Thompson, D. D. (2000) · Endocrinology · doi:10.1210/endo.141.4.7408 · Cited by 116

RU 58 668, a new pure antiestrogen inducing a regression of human mammary carcinoma implanted in nude mice

Velde, P. V. D., Nique, F., Bouchoux, F., Brémaud, J., HAMEAU, M., Lucas, D., Moratille, C., Viet, S., Philibert, D., & Teutsch, G. (1994) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(94)90144-9 · Cited by 116

Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats

Ke, H. Z., Simmons, H. A., Pirie, C. M., Crawford, D. T., & Thompson, D. D. (1995) · Endocrinology · doi:10.1210/endo.136.6.7750465 · Cited by 116

Effect of Dietary Fat on Human Breast Cancer Growth and Lung Metastasis in Nude Mice

Rose, D. P., Connolly, J. M., & Meschter, C. L. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.20.1491 · Cited by 116

Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro.

Gottardis, M. M., Wagner, R. J., Borden, E. C., & Jordan, V. C. (1989) · PubMed · Cited by 116

EFFECT OF SOME TRIPHENYLETHYLENES ON OESTRADIOL BINDING IN VITRO TO MACROMOLECULES FROM UTERUS AND ANTERIOR PITUITARY

Skidmore, J. C., Walpole, A. L., & Woodburn, J. R. (1972) · Journal of Endocrinology · doi:10.1677/joe.0.0520289 · Cited by 114

Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer.

Vogel, C. L., Shemano, I., Schoenfelder, J. R., et al. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.2.345 · Cited by 114

Transcription and Translation of Estrogen Receptor- in the Male Reproductive Tract of Estrogen Receptor- Knock-Out and Wild-Type Mice

Rosenfeld, C. S., Ganjam, V. K., Taylor, J. A., Yuan, X., Stiehr, J. R., Hardy, M. P., & Lubahn, D. B. (1998) · Endocrinology · doi:10.1210/endo.139.6.6028 · Cited by 113

EM-800, a Novel Antiestrogen, Acts as a Pure Antagonist of the Transcriptional Functions of Estrogen Receptors and

Tremblay, A., Tremblay, G. B., Labrie, C., Labrie, F., & Giguère, V. (1998) · Endocrinology · doi:10.1210/endo.139.1.5702 · Cited by 105

Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer.

Suh, N., Glasebrook, A. L., Palkowitz, A. D., Bryant, H. U., Burris, L. L., Starling, J. J., Pearce, H. L., Williams, C. R., Peer, C. W., Wang, Y., et al. (2001) · PubMed · Cited by 104

Docking Phospholipase A 2 on Membranes Using Electrostatic Potential-Modulated Spin Relaxation Magnetic Resonance

Lin, Y., Nielsen, R. D., Murray, D., Hubbell, W. L., Mailer, C., Robinson, B. H., & Gelb, M. H. (1998) · Science · doi:10.1126/science.279.5358.1925 · Cited by 102

INCREASES IN STEROID BINDING GLOBULINS INDUCED BY TAMOXIFEN IN PATIENTS WITH CARCINOMA OF THE BREAST

SAKAI, F., CHEIX, F., CLAVEL, M., COLON, J., MAYER, M., POMMATAU, E., & SAEZ, S. (1978) · Journal of Endocrinology · doi:10.1677/joe.0.0760219 · Cited by 102

The estrogen antagonist ICI 182,780 reduces cancellous bone volume in female rats

Gallagher, A. C., Chambers, T. J., & Tobias, J. H. (1993) · Endocrinology · doi:10.1210/endo.133.6.8243306 · Cited by 100

Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer

Newman, S. P., Bates, N. P., Vernimmen, D., Parker, M. G., & Hurst, H. C. (2000) · Oncogene · doi:10.1038/sj.onc.1203416 · Cited by 100

Effects of Tamoxifen Treatment on Plasma Lipids and Lipoprotein Lipid Composition

Bagdade, J. D., Wolter, J. M., Subbaiah, P. V., et al. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-70-4-1132 · Cited by 100

Antiestrogen can establish nonproductive receptor complexes and alter chromatin structure at target enhancers.

Pham, T. A., Elliston, J. F., Nawaz, Z., McDonnell, D. P., Tsai, M., & O’Malley, B. W. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.8.3125 · Cited by 97

Activation of the p38 Mitogen-activated Protein Kinase Pathway by Estrogen or by 4-Hydroxytamoxifen Is Coupled to Estrogen Receptor-induced Apoptosis

Zhang, C. C., & Shapiro, D. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.479 · Cited by 95

Toremifene and tamoxifen in advanced breast cancer - a double-blind cross-over trial

Stenbygaard, L. E., Herrstedt, J., Thomsen, J. F., et al. (1993) · Breast Cancer Research and Treatment · doi:10.1007/bf00662401 · Cited by 95

Antiestrogenic action of toremifene on hormone-dependent, -independent, and heterogeneous breast tumor growth in the athymic mouse.

Robinson, S. P., & Jordan, V. C. (1989) · PubMed · Cited by 95

MEKK1 Activation of Human Estrogen Receptor and Stimulation of the Agonistic Activity of 4-Hydroxytamoxifen in Endometrial and Ovarian Cancer Cells

Lee, H., Jiang, F., Wang, Q., Nicosia, S. V., Yang, J., Su, B., & Bai, W. (2000) · Molecular Endocrinology · doi:10.1210/mend.14.11.0554 · Cited by 95

Rat, but not human, sulfotransferase activates a tamoxifen metabolite to produce DNA adducts and gene mutations in bacteria and mammalian cells in culture

Glatt, H. R. (1998) · Carcinogenesis · doi:10.1093/carcin/19.10.1709 · Cited by 92

Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells

Wiseman, L. R., Johnson, M. D., Wakeling, A. E., Lykkesfeldt, A. E., May, F. E. B., & Westley, B. R. (1993) · European Journal of Cancer · doi:10.1016/0959-8049(93)90218-5 · Cited by 87

1-(Aminoalkyl)-2-phenylindoles as novel pure estrogen antagonists

Angerer, E. V., Knebel, N. G., Kager, M., & Ganss, B. (1990) · Journal of Medicinal Chemistry · doi:10.1021/jm00171a045 · Cited by 87

Human breast cancer cell lines resistant to pure anti‐estrogens are sensitive to tamoxifen treatment

Lykkesfeldt, A. E., Larsen, S. S., & Briand, P. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910610417 · Cited by 86

Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vitro.

Murphy, C. S., Langan-Fahey, S. M., McCague, R., et al. (1990) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09527-6 · Cited by 85

Characterization of a receptor-negative, hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditions.

Murphy, C. S., Pink, J. J., & Jordan, V. C. (1990) · PubMed · Cited by 84

Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer.

Chander, S. K., McCague, R., Luqmani, Y. A., et al. (1991) · PubMed · Cited by 84

ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer

Stål, O., Borg, Å., Fernö, M., Källström, A.-C., Malmström, P., & Nordenskjöld, B. A. (2000) · Annals of Oncology · doi:10.1023/a:1008313310474 · Cited by 82

Synthesis and biological activity of new halo-steroidal antiestrogens.

Levesque, C., Merand, Y., Dufour, J. M., Labrie, C., & Labrie, F. (1991) · Journal of Medicinal Chemistry · doi:10.1021/jm00109a014 · Cited by 81

Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models.

Blackwell, K. L., Haroon, Z. A., Shan, S., Saito, W., Broadwater, G., Greenberg, C. S., & Dewhirst, M. W. (2000) · PubMed · Cited by 81

Structural differences between the hormone and antihormone estrogen receptor complexes bound to the hormone response element.

Sabbah, M., Gouilleux, F., Sola, B., Redeuilh, G., & Baulieu, E. E. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.2.390 · Cited by 81

Sulfation of alpha-hydroxytamoxifen catalyzed by human hydroxysteroid sulfotransferase results in tamoxifen-DNA adducts

Shibutani, S. (1998) · Carcinogenesis · doi:10.1093/carcin/19.11.2007 · Cited by 80

Interaction and Dissociation by Ligands of Estrogen Receptor and Hsp90: The Antiestrogen RU 58668 Induces a Protein Synthesis-Dependent Clustering of the Receptor in the Cytoplasm

Leclerc, J., Meng, X., Delahaye, F., Leclerc, P., Baulieu, É.-É., & CATELLI, M. G. (1998) · Molecular Endocrinology · doi:10.1210/mend.12.6.0121 · Cited by 78

Effect of long-term tamoxifen therapy on cancellous bone remodeling and structure in women with breast cancer

Wright, C. D. P., Garrahan, N. J., Stanton, M., Gazet, J. C., Mansell, R., & Compston, J. E. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090204 · Cited by 76

Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cellsin vitro

Simard, J., Labrie, C., Bélanger, A., Gauthier, S., Singh, S. M., Mérand, Y., & Labrie, F. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970926)73:1<104::aid-ijc16>3.0.co;2-g · Cited by 75

Novel compounds inhibit estrogen formation and action.

Labrie, C., Martel, C., Dufour, J. M., Lévesque, C., Mérand, Y., & Labrie, F. (1992) · PubMed · Cited by 74

Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines

Tonetti, D. A., Chisamore, M. J., Grdina, W. L., Schurz, H., & Jordan, V. C. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1326 · Cited by 74

Antiestrogens inhibit endothelial cell growth stimulated by angiogenic growth factors.

Gagliardi, A. R., Hennig, B., & Collins, D. C. (1996) · PubMed · Cited by 74

Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells.

Simard, J., Sanchez, R., Poirier, D., et al. (1997) · PubMed · Cited by 72

Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat

di Salle, E., Zaccheo, T., & Ornati, G. (1990) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(90)90005-d · Cited by 68

The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor.

Schafer, J. M., Liu, H., Tonetti, D. A., & Jordan, V. C. (1999) · PubMed · Cited by 65

Insulin Inhibits the Activation of Transcription by a C-terminal Fragment of the Forkhead Transcription Factor FKHR

Tomizawa, M., Kumar, A., Perrot, V., Nakae, J., Accili, D., & Rechler, M. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.10.7289 · Cited by 65

Effects of the antiestrogen tamoxiten on low-density lipoprotein concentrations and oxidation in postmenopausal women

Guetta, V., Lush, R. M., Figg, W. D., et al. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80302-6 · Cited by 64

Tamoxifen as a possible chemotherapeutic agent in endometrial adenocarcinoma

Bonte, J., Ide, P. S., Billiet, G., & Wynants, P. (1981) · Gynecologic Oncology · doi:10.1016/s0090-8258(81)80003-0 · Cited by 64

Effects of Raloxifene After Tamoxifen on Breast and Endometrial Tumor Growth in Athymic Mice

O'Regan, R. M., Gajdos, C., Dardes, R. C., et al. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.4.274 · Cited by 64

Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen

Herman, M. E., & Katzenellenbogen, B. S. (1996) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(96)00114-8 · Cited by 61

Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha.

Chisamore, M. J., Ahmed, Y., Bentrem, D. J., Jordan, V. C., & Tonetti, D. A. (2001) · PubMed · Cited by 60

Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.

Johnston, S. R. D., Boeddinghaus, I., Riddler, S., Haynes, B. P., Hardcastle, I. R., Rowlands, M. G., Grimshaw, R., Jarman, M., & Dowsett, M. (1999) · PubMed · Cited by 58

Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat

Martel, C., Picard, S., Richard, V., Bélanger, A., Labrie, C., & Labrie, F. (2000) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(00)00087-x · Cited by 57

Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 rats

Dragan, Y. P., Fahey, S., Street, K., et al. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00689673 · Cited by 55

Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)

Wang, J., Sánchez-Roselló, M., Aceña, J. L., del Pozo, C., Sorochinsky, A. E., Fustero, S., Soloshonok, V. A., & Liu, H. (2014) · Chemical Reviews · doi:10.1021/cr4002879 · Cited by 4,847

Modern Synthetic Methods for Fluorine‐Substituted Target Molecules

Shimizu, M., & Hiyama, T. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200460441 · Cited by 830

Estrogen receptors alpha (ERα) and beta (ERβ): Subtype-selective ligands and clinical potential

Paterni, I., Granchi, C., Katzenellenbogen, J. A., & Minutolo, F. (2014) · Steroids · doi:10.1016/j.steroids.2014.06.012 · Cited by 721

Structural Overview of the Nuclear Receptor Superfamily: Insights into Physiology and Therapeutics

Huang, P., Chandra, V., & Rastinejad, F. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135917 · Cited by 533

Resveratrol as an anticancer nutrient: molecular basis, open questions and promises

Signorelli, P., & Ghidoni, R. (2005) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2005.01.017 · Cited by 489